BMY logo

BRISTOL-MYERS SQUIBB CO

BMYNYSE
πŸ† #112 by market capEarnings Oct 29🧬Biotech
$60.57β–Ό $0.98 (βˆ’1.59%)
πŸŒ™ After hours$61.75β–² 1.95%Regular close Β· extended-hours price shown
πŸ””
Track BMY
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.6%
7dβ–Ό 1.0%
14dβ–² 2.2%
30dβ–Ό 5.2%
ytdβ–² 12.3%
1yβ–² 41.4%
🏦Market Cap
$123.73B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
3.1%
Slowing
πŸ“ŠGross Margin
71.7%
High
πŸ’΅FCF Margin
33.9%
Strong
βš–οΈP/S Ratio
2.5x
Cheap
Otter Score
72
Strong

Trading Snapshot

Day Range
$60.33 – $61.33
52-Week Range
$42.52 – $68.64
Volume (shares)
7,409,824
Avg Volume (shares)
β€”
Shares Outstanding
2.04B
Next Earnings
2026-10-29

Fundamentals Snapshot

Annual Revenue
$48.20B
Last Q Revenue
$12.97B
P/E Ratio
13.5
P/S Ratio
2.5x
EPS (TTM)
$4.54
Dividend Yield
6.06%
Dilution (1yr)
+0.2%
BMY logo

BRISTOL-MYERS SQUIBB CO

BMY
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$48.2Bβ–Ό βˆ’0.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
71.1%β–² +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$13.7Bβ–² +133.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$12.8Bβ–Ό βˆ’7.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.04Bβ–² +0.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$36.9Bβ–² +$3.9B YoY
StockOtter Β· stockotter.space

About BRISTOL-MYERS SQUIBB CO

Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organizations. Founded in 1887 and formerly known as Bristol-Myers Company, the firm maintains its headquarters in New York, New York.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
72/100
Analyst data unavailable.

Latest News & Updates

Fool - Investing NewsΒ·12h ago

3 Magnificent Dividend Stocks for Risk-Averse Investors

Every investment carries some measure of risk. These pose less risk than others that offer similar rewards.

Zacks Investment ResearchΒ·1d ago

What's in Store for These 5 Drug/Biotech Stocks in Q3 Earnings?

Biotech earnings take center stage as Bristol Myers, Eli Lilly, Merck, AbbVie and Gilead Sciences prepare to report Q3'26 results.

Defense WorldΒ·1d ago

8,656 Bristol Myers Squibb Company $BMY Shares Sold by Evergreen Capital Management LLC

Evergreen Capital Management LLC reduced its stake in Bristol Myers Squibb Company (NYSE: BMY) by 20.3% during the undefined quarter, according to the company in its most recent filing with the SEC. The fund owned 34,066

The Motley FoolΒ·1d ago

Bristol Myers Squibb's Cancer Drug Just Doubled Survival Time Without Progression β€” Here's Why It Matters

It also demonstrated very promising results when evaluated in other solid tumors. The company's involvement in the program is part of a broader effort to develop its burgeoning growth portfolio.

Zacks Investment ResearchΒ·2d ago

Should You Buy, Hold, or Sell BMY Stock Ahead of Q3 Earnings?

Bristol-Myers Squibb heads into Q3 earnings with growth drugs and higher Eliquis guidance offsetting legacy portfolio declines.

Fool - Investing NewsΒ·2d ago

3 Cheap Dividend Stocks I'd Buy Without Any Hesitation

Don't overthink it. These are blue chip stocks that have simply gone on sale and would be solid additions to almost any income portfolio.